Breast Cancer Research and Treatment

, Volume 149, Issue 1, pp 269–275 | Cite as

Fulvestrant and male breast cancer: a pooled analysis

  • Flora Zagouri
  • Theodoros N. Sergentanis
  • Dimosthenis Chrysikos
  • Meletios-Athanasios Dimopoulos
  • Theodora Psaltopoulou
Epidemiology

Abstract

Male breast cancer is an uncommon malignancy; little is known regarding hormonal manipulations for tamoxifen-resistant male breast cancer patients. This is the first pooled analysis of the literature to synthesize all available data and to evaluate the efficacy and safety of fulvestrant in male breast cancer. This study was performed in accordance with the PRISMA guidelines. All studies that examined the efficacy of fulvestrant in male breast cancer, regardless of sample size, were considered eligible. The search strategy retrieved 31 articles; of these, five articles were eligible (23 patients) for this pooled analysis. The mean age of the study sample was 63.1 years. Adjuvant hormonal treatment was administered in 87.5 % of cases. Fulvestrant was given as first or second line in 40 % of patients, while as third line or beyond in 60 % of patients. 79.0 % of patients at fulvestrant administration had visceral metastases. Regarding best response, in 26.1 % PR was achieved, in 47.8 % of cases SD was recorded, whereas in 26.1 % of patients PD was noted. The median PFS was equal to 5 months. No grade 3 and 4 adverse events were recorded; of note, hot flashes were reported in 18.2 % of male breast cancer patients. Fulvestrant may potentially play a promising role in the optimal therapeutic strategy for male patients with breast cancer diagnosis. However, further clinical and pharmacokinetic investigations are more than warranted before fulvestrant use becomes a common practice in male breast cancer patients.

Keywords

Male breast cancer Fulvestant Hormonal treatment Therapy Pooled analysis 

References

  1. 1.
    Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, Schatzkin A (2008) Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 100:1477–1481PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3 (2014). Available at www.nccn.com
  3. 3.
    Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871–1888PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23:489–502PubMedCrossRefGoogle Scholar
  5. 5.
    Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M (2002) Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81:333–341PubMedCrossRefGoogle Scholar
  6. 6.
    Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M (2014) Final overall survival: fulvestrant 500 mg versus 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106(1):djt337PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664–1670PubMedCrossRefGoogle Scholar
  8. 8.
    Liberati A, Altman DG, Tetzlaff J (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34PubMedCrossRefGoogle Scholar
  9. 9.
    Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G, Zografos G, Bartsch R (2013) Fulvestrant and male breast cancer: a case series. Ann Oncol 24:265–266PubMedCrossRefGoogle Scholar
  10. 10.
    Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R (2011) A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat 129:819–827PubMedCrossRefGoogle Scholar
  11. 11.
    Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA (2011) Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 17:4799–4805PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, De Greve J, Fontaine C, Van Den Weyngaert D, Becquart D, Borms M, Cocquyt V, Van Den Broecke R, Selleslags J, Awada A, Dirix L, Van Dam P, Azerad MA, Vandenhoven G, Christiaens MR, Vergote I (2008) Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 109:59–65PubMedCrossRefGoogle Scholar
  13. 13.
    Masci G, Gandini C, Zuradelli M, Pedrazzoli P, Torrisi R, Lutman FR, Santoro A (2011) Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol 22:985PubMedCrossRefGoogle Scholar
  14. 14.
    de la Haba Rodríguez JR, Quintela IP, Cortijo GP, Guerrero MB, Aranda E (2009) Fulvestrant in advanced male breast cancer. Ann Oncol 20:1896–1897PubMedCrossRefGoogle Scholar
  15. 15.
    Agrawal A, Cheung KL, Robertson JF (2007) Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 101:123PubMedCrossRefGoogle Scholar
  16. 16.
    Carmona-Bayonas A (2007) Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer. Breast 16:323–325PubMedCrossRefGoogle Scholar
  17. 17.
    Onami S, Ozaki M, Mortimer JE, Pal SK (2010) Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas 65:308–314PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH (1998) Molecular markers in male breast carcinoma. Cancer 83:1947–1955PubMedCrossRefGoogle Scholar
  19. 19.
    Stalsberg H, Thomas DB, Rosenblatt KA, Jimenez LM, McTiernan A, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF et al (1993) Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control 4:143–151PubMedCrossRefGoogle Scholar
  20. 20.
    Farrow JH, Adair FE (1942) Effect of orchidectomy on skeletal metastases from cancer of the male breast. Science 95:654PubMedCrossRefGoogle Scholar
  21. 21.
    White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V (2011) Male breast carcinoma: increased awareness needed. Breast Cancer Res 13:219PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Arriola E, Hui E, Dowsett M, Smith IE (2007) Aromatase inhibitors and male breast cancer. Clin Transl Oncol 9:192–194PubMedCrossRefGoogle Scholar
  23. 23.
    Giordano SH, Valero V, Buzdar AU, Hortobagyi GN (2002) Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25:235–237PubMedCrossRefGoogle Scholar
  24. 24.
    Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G (1983) Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143:237–240PubMedCrossRefGoogle Scholar
  25. 25.
    Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos MA, Bartsch R (2013) Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108:2259–2263PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Giordano SH, Hortobagyi GN (2006) Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24:e42–e43PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Flora Zagouri
    • 1
  • Theodoros N. Sergentanis
    • 2
  • Dimosthenis Chrysikos
    • 1
  • Meletios-Athanasios Dimopoulos
    • 1
  • Theodora Psaltopoulou
    • 2
  1. 1.Department of Clinical Therapeutics, Medical School, Alexandra HospitalUniversity of AthensAthensGreece
  2. 2.Department of Hygiene, Epidemiology and Medical Statistics, Medical SchoolUniversity of AthensAthensGreece

Personalised recommendations